News & Events

Cardiff, UK, Press Release 26th June 2024

Cardiff Scintigraphics has appointed John Pritchard as the new Chairman of the Board of Directors with effect from 27th June 2024. John will be succeeding Dr David Owen who will be stepping down as a member of the Board. We would like to thank David for his support and Chairmanship over the past 5 years and he will remain as a consultant for the company to support the next stage of growth.

John is an internationally recognised expert and leader in Inhalation Product Development, with experience across a range of companies including GSK, 3M, AZ and Phillips Healthcare. He has published extensively in the field of inhaled drug delivery and received the prestigious Charles G Thiel award at RDD in 2018. John has expressed his enthusiasm to chair CSL/i2c saying “I’m looking forward to the challenge of stepping into David’s role at what I think will be very exciting times for the company. The Board combines well over 100 years’ experience in the development of respiratory products and so I will have tremendous support from the team”

“John brings a wealth of experience at executive level to CSL/i2c and will play a strong role in the next phase of the company’s expansion and he has the unanimous support of the Board” said Andrew Brown, CEO of CSL/i2c. Founded in 1992, CSL/i2c is a leading contract research centre of excellence for inhaler development and testing, enabling the transitions from inception of concept and research data, fast-tracking through to clinical trials. For more information, please visit the company’s websites www.scintigraphics.co.uk or www.i2cpharm.co.uk, or contact Andrew.Brown@i2cpharm.co.uk or phone +44 29 2075 7865.

Cardiff, UK, Press Release 30 May 2024

Cardiff Scintigraphics has appointed Andrew Brown as the new Chief Executive Officer and member of the Board of Directors, with effect from 03 June 2024. Andrew will be succeeding Glyn Taylor who will remain as a member of the Board and as Chief Scientific Officer in a part-time capacity.

Andrew is a proven leader and brings a wealth of experience over 20 years in senior pharmaceutical development, device development and operations in the pharmaceutical industry, with Sanofi-Aventis, GSK, Oriel and most recently, OBG Pharmaceuticals.

“I am honoured to lead such a talented team at CSL/i2c during this pivotal time. CSL/i2c’s unique offering and strong IP provide a great platform for future growth” said Andrew Brown.

“Andrew is clearly an inspiring person with the qualities and experience to lead CSL/i2c through the next phase of the company’s expansion and he has the unanimous support of the Board” said Glyn Taylor current CEO and a Founding Director of CSL/i2c.

Established in 1992, CSL/i2c is a leading contract research centre of excellence for inhaler development and testing, enabling the transitions from inception of concept and initial research findings through fast-tracking to clinical testing.

The Drug Delivery to the Lungs Conference (DDL) is in it’s 34th year and attracts in excess of 1000 attendees worldwide, including scientists, academics, clinicians, regulators and industry experts.

The conference includes a large industry exhibition, supported by over 100 international companies, a scientific poster hall, expert lectures and excellent networking opportunities over the 3-day event.

DDL actively supports young scientists by offering free registration for students, Career Development Grants and a variety of awards, recognising their achievements.

DDL attracts a wide variety of attendees, including scientists, academics, clinicians, regulators and industry experts.

DDL offers the opportunity for lectures, posters and exhibitions to be closely located thereby enhancing interactions and networking opportunities for attendees, presenters and exhibitors.

DDL is a not-for-profit conference and any surplus funds are provided as grants or awards, targeting research and training of the next generation of aerosol and drug delivery scientists.